Edward Kim, MD
Vascular & Interventional Radiology · New York, NYNPI 1851565543
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 76.2% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $222,093, 4.3 times the $52,013 reported in 2019. Among vascular & interventional radiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 753 payments — averaging $1103.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$633K
- Siemens Medical Solutions USA, Inc.$41K
- Biocompatibles, Inc.$27K
- Medical Device Business Services, Inc.$18K
- AstraZeneca$17K
- Philips North America LLC$14K
- plus $80K from 25 others
Across 28 payments — averaging $987.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$18K
- Merit Medical Systems Inc$7K
- Regeneron$2K
- Novartis$1K
What the payments were for
- Consulting fees$318,45938%
- Speaking & faculty fees$418,28750%
- Grants$1,8000%
- Travel & lodging$64,5378%
- Food & beverage$27,6753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 542 | $632,926 |
| Siemens Medical Solutions USA, Inc. | 28 | $41,351 |
| Biocompatibles, Inc. | 23 | $27,222 |
| Medical Device Business Services, Inc. | 11 | $17,651 |
| AstraZeneca | 17 | $17,169 |
| Philips North America LLC | 15 | $13,977 |
| Eisai Inc. | 7 | $13,150 |
| Johnson & Johnson | 44 | $11,240 |
| Sirtex Medical Inc | 3 | $10,000 |
| Genentech USA, Inc. | 11 | $9,184 |
| E.r. Squibb & Sons, L.L.C. | 2 | $6,900 |
| Astrazeneca UK Limited | 5 | $6,848 |
| Bard Peripheral Vascular, Inc. | 11 | $5,909 |
| Ethicon Endo-surgery Inc. | 3 | $4,140 |
| Genentech, Inc. | 6 | $3,538 |
| Bayer | 1 | $3,250 |
| Terumo Medical Corporation | 7 | $2,292 |
| Trisalus Life Sciences, Inc. | 1 | $1,200 |
| Guerbet LLC | 1 | $1,000 |
| Medical Templates AG | 1 | $550 |
| Cook Medical LLC | 1 | $250 |
| Histosonics, Inc. | 2 | $215 |
| Recor Medical Inc | 2 | $173 |
| Penumbra, Inc. | 1 | $164 |
| Mediview XR, Inc. | 1 | $140 |
| Dova Pharmaceuticals | 1 | $123 |
| BTG International Canada Inc. | 2 | $80 |
| Cvrx, Inc. | 1 | $43 |
| Balt USA, LLC | 1 | $35 |
| Angiodynamics, Inc. | 1 | $23 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial)$260,390
- TheraSphere Y90 Glass Microspheres 10 GBq$199,848
- GENERAL - THERAPIES$60,076
- THERASPHERE-BIO$27,577
- THERASPHERE$20,096
- GENERAL VASCULAR INTERVENTION$18,484
- GENERAL PAIN MANAGEMENT$18,423
- GENERAL - IO ABLATION$15,535
- Certus 140$15,210
- LENVIMA$12,290
- SIR-Spheres Microspheres$10,000
- IMFINZI$9,508
- DIREXION$9,500
- TECENTRIQ$9,095
- CODMAN CERTAS$8,190
- DERMABOND$8,190
- MONOCRYL$8,190
- IGT Systems Und$7,953
- GENERAL EMBOLICS$5,250
- Varian Treatment$4,340
How this compares
$830,758 in reported general payments places this provider in the 95th percentile of 306 vascular & interventional radiology providers in New York.
See all vascular & interventional radiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 27 | $98 |
Paid to pharmacies, not to this prescriber.
Other vascular & interventional radiology in New York
- Robert LooksteinNew York$515K
- Rahul PatelNew York$275K
- Aaron FischmanNew York$240K
- Philip MeyersNew York$238K
- Abigail FalkNew York$214K
- Robert RosenNew York$199K
- Asad BaigNew York$137K
- Joshua WeintraubNew York$137K
- Joseph ShamsNew York$136K
- Ryan HickeyNew York$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.